184 related articles for article (PubMed ID: 37327122)
1. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
Brown-Burke F; Hwang I; Sloan S; Hinterschied C; Helmig-Mason J; Long M; Chan WK; Prouty A; Chung JH; Zhang Y; Singh S; Youssef Y; Bhagwat N; Chen Z; Chen-Kiang S; Di Liberto M; Elemento O; Sehgal L; Alinari L; Vaddi K; Scherle P; Lapalombella R; Paik J; Baiocchi RA
Blood Adv; 2023 Oct; 7(20):6211-6224. PubMed ID: 37327122
[TBL] [Abstract][Full Text] [Related]
2. Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME; Koirala S; Sloan S; Brown-Burke F; Weigel C; Villagomez L; Corps K; Sharma A; Hout I; Harper M; Helmig-Mason J; Tallada S; Chen Z; Scherle P; Vaddi K; Chen-Kiang S; Di Liberto M; Meydan C; Foox J; Butler D; Mason C; Alinari L; Blaser BW; Baiocchi R
Blood Adv; 2024 Jan; 8(1):150-163. PubMed ID: 37782774
[TBL] [Abstract][Full Text] [Related]
3. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
[TBL] [Abstract][Full Text] [Related]
4. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL; Brown F; Long M; Weigel C; Koirala S; Chung JH; Pray B; Villagomez L; Hinterschied C; Sircar A; Helmig-Mason J; Prouty A; Brooks E; Youssef Y; Hanel W; Parekh S; Chan WK; Chen Z; Lapalombella R; Sehgal L; Vaddi K; Scherle P; Chen-Kiang S; Di Liberto M; Elemento O; Meydan C; Foox J; Butler D; Mason CE; Baiocchi RA; Alinari L
Blood; 2023 Sep; 142(10):887-902. PubMed ID: 37267517
[TBL] [Abstract][Full Text] [Related]
5. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
6. Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.
Thus YJ; De Rooij MFM; Swier N; Beijersbergen RL; Guikema JEJ; Kersten MJ; Eldering E; Pals ST; Kater AP; Spaargaren M
Haematologica; 2023 Mar; 108(3):797-810. PubMed ID: 36226498
[TBL] [Abstract][Full Text] [Related]
7. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.
Dengler MA; Teh CE; Thijssen R; Gangoda L; Lan P; Herold MJ; Gray DH; Kelly GL; Roberts AW; Adams JM
Oncogene; 2020 Feb; 39(9):2009-2023. PubMed ID: 31772331
[TBL] [Abstract][Full Text] [Related]
8. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
Thus YJ; Eldering E; Kater AP; Spaargaren M
Leukemia; 2022 Sep; 36(9):2165-2176. PubMed ID: 35725771
[TBL] [Abstract][Full Text] [Related]
9. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
10. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.
Montraveta A; Xargay-Torrent S; Rosich L; López-Guerra M; Roldán J; Rodríguez V; Lee-Vergés E; de Frías M; Campàs C; Campo E; Roué G; Colomer D
Oncotarget; 2015 Aug; 6(25):21159-72. PubMed ID: 26110568
[TBL] [Abstract][Full Text] [Related]
12. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
13. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
Thieme E; Liu T; Bruss N; Roleder C; Lam V; Wang X; Nechiporuk T; Shouse G; Danilova OV; Bottomly D; McWeeney SK; Tyner JW; Kurtz SE; Danilov AV
Cell Death Dis; 2022 Mar; 13(3):246. PubMed ID: 35296646
[TBL] [Abstract][Full Text] [Related]
14. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.
O'Steen S; Green DJ; Gopal AK; Orozco JJ; Kenoyer AL; Lin Y; Wilbur DS; Hamlin DK; Fisher DR; Hylarides MD; Gooley TA; Waltman A; Till BG; Press OW
Cancer Res; 2017 Jul; 77(14):3885-3893. PubMed ID: 28566329
[TBL] [Abstract][Full Text] [Related]
16. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Chan-Penebre E; Kuplast KG; Majer CR; Boriack-Sjodin PA; Wigle TJ; Johnston LD; Rioux N; Munchhof MJ; Jin L; Jacques SL; West KA; Lingaraj T; Stickland K; Ribich SA; Raimondi A; Scott MP; Waters NJ; Pollock RM; Smith JJ; Barbash O; Pappalardi M; Ho TF; Nurse K; Oza KP; Gallagher KT; Kruger R; Moyer MP; Copeland RA; Chesworth R; Duncan KW
Nat Chem Biol; 2015 Jun; 11(6):432-7. PubMed ID: 25915199
[TBL] [Abstract][Full Text] [Related]
17. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
[TBL] [Abstract][Full Text] [Related]
18. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
19. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.
Beltran E; Fresquet V; Martinez-Useros J; Richter-Larrea JA; Sagardoy A; Sesma I; Almada LL; Montes-Moreno S; Siebert R; Gesk S; Calasanz MJ; Malumbres R; Rieger M; Prosper F; Lossos IS; Piris MA; Fernandez-Zapico ME; Martinez-Climent JA
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12461-6. PubMed ID: 21746927
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
